Methotrexate Teva

Methotrexate, the active ingredient in Methotrexate Teva, is a folate antagonist presented as a parenteral preparation for epidural, intrabursal, and intracoronary administration. It is employed in the management of rheumatoid arthritis, psoriasis, certain leukemias, osteosarcoma, and ectopic pregnancy in adult patients.

GNH USA supplies Methotrexate Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Methotrexate Teva acts as a folate pathway inhibitor used across several disease families. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: diminishes skin plaque formation and severity. - Acute lymphoblastic leukemia: interferes with malignant cell proliferation. - Osteosarcoma: limits tumor growth in bone. - Ectopic pregnancy: halts trophoblastic tissue development.

Methotrexate may cause a range of adverse reactions.

Common Side Effects: - Nausea and vomiting. - Fatigue or malaise. - Oral mucosal ulceration. - Mild liver enzyme elevation. - Transient low white blood cell count. - Mild skin rash.

Serious or Rare Side Effects: - Severe hepatotoxicity or fibrosis. - Pulmonary fibrosis or interstitial pneumonitis. - Life‑threatening bone marrow suppression. - Acute renal failure. - Severe cutaneous adverse reactions (e.g., Stevens‑Johnson syndrome). - Opportunistic infections due to immunosuppression.

Before initiating therapy, several safety considerations are required. - Pregnancy: contraindicated (Category X) – avoid use in pregnant women. - Renal function: assess baseline creatinine and adjust if impaired. - Liver function: monitor transaminases regularly. - Hematologic status: perform complete blood counts before and during treatment. - Drug interactions: review concomitant medications for potential additive toxicity. - Store at ambient temperature: keep in original container, protect from moisture and light.

Methotrexate interacts with several medicines that may alter its safety or efficacy.

Major Interactions (Avoid): - NSAIDs: increase risk of renal toxicity and gastrointestinal ulceration. - Trimethoprim‑sulfamethoxazole: potentiate bone‑marrow suppression. - Live vaccines: heightened risk of infection. - Radiation therapy: may exacerbate tissue damage.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may affect methotrexate absorption. - Leucovorin rescue: dosing adjustments may be needed. - Azathioprine: additive immunosuppressive effect requiring close monitoring.